← Drug database

Levetiracetam Sun (levetiracetam)

Generic
Region
🇪🇺 EU
Active substance
levetiracetam
Company
Sun Pharmaceutical Industries Europe B.V.
Status
Authorised
Therapeutic area
Epilepsy
CHMP opinion
Thu 20 Oct 2011
EU approval
Wed 14 Dec 2011
Designations
Generic
Application
EMEA/H/C/002051
ATC
N03AX14
Official record
www.ema.europa.eu

Indication

Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Levetiracetam Sun is indicated as adjunctive therapy: in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy; in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy; in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy. Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Levetiracetam Sun

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.